Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration

Trial Profile

A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs 4D-150 (Primary) ; Aflibercept
  • Indications Wet age-related macular degeneration
  • Focus Adverse reactions
  • Acronyms PRISM
  • Sponsors 4D Molecular Therapeutics

Most Recent Events

  • 06 Nov 2025 According to a 4D Molecular Therapeutics media release, data will be presented in detail at an upcoming scientific conference.
  • 06 Nov 2025 Interim results presented in a 4D Molecular Therapeutics media release.
  • 24 Jul 2025 According to a 4D Molecular Therapeutics media release, results from this trial will be presented at the 43rd Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) being held in Long Beach, CA, on August 1, 2025 (11:24 - 11:27 a.m. PT), by John A. Wells.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top